Danish pharmaceutical company Novo Nordisk (NYSE: NVO) is pioneering a new wave of medical treatment for diabetes and obesity ...
The active ingredient in Ozempic and Wegovy has once again proven to have health effects outside of weight loss in a huge ...
Critics, including Senator Bernie Sanders, question whether the push to block alternatives is truly about safety — or simply ...
Novo Nordisk is urging the U.S. Food and Drug Administration (FDA) to block ‘copycat’ versions of its popular weight-loss and ...
The full-year cost of care for U.S. patients with obesity, two years after starting on Novo Nordisk's Wegovy or similar GLP-1 ...
The University of California, Davis today announced an expanded collaboration with the BioInnovation Institute (BII) to ...
A new class of weight-loss drugs is changing the food industry, but not in the way many expected at first. They could present ...
City employees in NYC had insurance coverage for GLP-1 drugs like Wegovy and Zepbound for less than a year before learning it ...
In Quebec, anti-obesity medications are on the list of exclusions of the Régie de l’assurance maladie du Québec (RAMQ). Quebec is the only Canadian province that does not evaluate obesity medications ...
Semaglutide outperformed 7 diabetes medications in reducing risk of Alzheimer's disease, according to a study of over 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback